Digest Network Come funziona
Network
/
Società
Pu
Non verificato

PureTech Health plc

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteScienza

48 comunicati stampa

Guarda tutti i comunicati
06/01/2026
Biotecnologia
Farmaceutica
Salute
Eventi
Web e Social Network
PureTech to Present at 44th Annual J.P. Morgan Healthcare Conference
Fonte
PureTech Health plc
Emittente
Business Wire
1.00
0
18/12/2025
PureTech Appoints Robert Lyne as Chief Executive Officer
Fonte
PureTech Health plc
Emittente
Business Wire
1.00
0
08/12/2025
Multimedialità
Igiene alimentare
Salute
Medicina - Varie
Sanità
Farmaceutica
Biotecnologia
PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis
Fonte
PureTech Health plc
Emittente
Business Wire
1.00
0
05/12/2025
Multimedialità
Industria
Eventi
Oncologia
Salute
Igiene alimentare
Medicina - Varie
Farmaceutica
Biotecnologia
PureTech’s Founded Entity Gallop Oncology Announces Positive Initial Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
Fonte
PureTech Health plc
Emittente
Business Wire
1.00
0
03/11/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Eventi
Industria
PureTech’s Founded Entity Gallop Oncology to Present New Data from Ongoing Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia (AML) at the American Society of Hematology (ASH) Annual Meeting
Fonte
PureTech Health plc
Emittente
Business Wire
1.00
0
22/10/2025
Scienza
Terza età
Biotecnologia
Farmaceutica
Salute
Vetrine/Shopping
Medicina - Varie
Industria
PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with Idiopathic Pulmonary Fibrosis (IPF), a Historically Undertreated Group
Fonte
PureTech Health plc
Emittente
Business Wire
1.00
0
29/09/2025
PureTech Presents New Data from Phase 2b Open-Label Extension Study of Deupirfenidone (LYT-100), Further Supporting Strong and Durable Efficacy and Potential to Serve as New Standard of Care in IPF
Fonte
PureTech Health plc
Emittente
Business Wire
1.00
0
11/09/2025
Psichiatria
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
PureTech Founded Entity Seaport Therapeutics Advances Second Therapeutic Candidate into Clinical Development with Dosing of First Participant in Phase 1 Study of GlyphAgo™ (SPT-320) in Healthy Volunteers
Fonte
PureTech Health plc
Emittente
Business Wire
1.00
0
28/08/2025
Oncologia
Salute
Medicina - Varie
Sanità
Farmaceutica
Biotecnologia
Web e Social Network
Telefonia e Varie
Mercato azionario
PureTech Health plc – Half-Year Report
Fonte
PureTech Health plc
Emittente
Business Wire
1.00
0
21/08/2025
Oncologia
Salute
Medicina - Varie
Sanità
Farmaceutica
Biotecnologia
Eventi
Industria
PureTech Showcases Differentiated Development Strategy, Including New Patient Preference Insights, and Spotlights Phase 2b Data Positioning Deupirfenidone as a Potential New Standard of Care in IPF
Fonte
PureTech Health plc
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0